Disc Presents Initial Data From Ongoing Phase 1b/2 Trial Of DISC-0974 In Patients With Myelofibrosis And Anemia At The 65th American Society Of Hematology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine, Inc. (NASDAQ: IRON) reported positive initial data from its phase 1b/2 study of DISC-0974 in patients with Myelofibrosis (MF) and anemia at the ASH Annual Meeting. The data showed dose-dependent reductions in serum hepcidin and increases in serum iron, leading to improved hemoglobin levels and reduced transfusion burden. DISC-0974 was well-tolerated, and the study is ongoing with plans to present more data next year. The company will also discuss the phase 2 BEACON study of bitopertin in EPP.
December 11, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine announced positive initial results from its phase 1b/2 study of DISC-0974, showing potential in treating anemia in MF patients. The data was well-received, and the drug was generally well-tolerated.
The positive initial data from the ongoing trial of DISC-0974 suggests potential for the drug's efficacy and safety, which could lead to increased investor confidence and a positive short-term impact on IRON's stock price. The relevance of the news is high as it directly pertains to the company's lead clinical program. The importance is also high due to the potential market for anemia treatments in MF, which affects a significant patient population. The confidence in the analysis is strong given the clear positive results and the company's commitment to further development of the drug.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100